NAUT · 10-Q · 2026Q1 · Full report

Operating Cash Flow Trends

Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 43 · Surprise 32

Net cash used in operating activities was $13.1 million for the three months ended March 31, 2026, compared with $13.9 million in the year‑ago quarter. Q1 2026 operating cash use resulted from the net loss of $14.7 million and a $1.2 million decrease in net changes in assets and liabilities. Non‑cash charges included $1.4 million of stock‑based compensation, $1.1 million of amortization of operating lease right‑of‑use assets, and $0.3 million of depreciation, aggregating $2.8 million of non‑cash items included in operating cash flows. These dynamics indicate a quarterly cash burn roughly in line with reported operating losses and continued reliance on financing to fund operations.

Key facts

• Net cash used in operating activities was $13,100,000 for the three months ended March 31, 2026, and $13,937,000 for the three months ended March 31, 2025.
• Non-cash charges included in net cash used in operating activities for the three months ended March 31, 2026 aggregated $2.8 million and were driven by $1.4 million of stock-based compensation, $1.1 million of amortization of operating lease right-of-use assets, and $0.3 million of depreciation.
• Non-cash charges included in net cash used in operating activities for the three months ended March 31, 2025 aggregated $3.3 million and were driven by $2.2 million of stock-based compensation, $1.2 million of amortization of operating lease right-of-use assets, and $0.5 million of depreciation.